Is The Future Of Injectable Drug Delivery In Needle-Free Devices?

Injectable drug delivery is an ever evolving industry, and these days, its future seems to be headed toward an increase in needle-free devices

Avatar
January 28, 2019
1,248 Views

 

Administration of drugs for managing prevailing diseases is a common practice across the globe. The injectable drug delivery approach includes the use of needles or similar objects that are penetrated into the skin for drug administration. There a lot of effort put into improving the experience of patients during injectable drug delivery with the help of reminders, connectivity to smartphones, self-use devices, and others.

Moreover, the advent of self-injection devices including pen injectors, auto-injectors, and needle-free injectors, has made the use of injectable drug delivery comparatively easier. Furthermore, the prevalence of the self-care trend where patients prefer drug administration in the convenience of their home deprived of any medical assistance is further boosting new developments in the injectable drug delivery landscape.

Could Needle-free Injectors Mark the Future of Injectable Drug Delivery?

All the medical devices are developed with an aim to simplify therapeutics and drug delivery for patients. The pharmaceutical companies are revolutionizing the way injectable drug delivery is conducted by removing the need for needles and syringes. This not only offers a pain-free and rapid experience of drug administration for patients but also contributes to waste reduction.  There are several developments witnessed in line with the growing demand for needle-free injectors, with respect to its manufacturing.

For instance, the Beijing-based QS Medical Technology Co., Ltd. unveiled its new needle-free injection technology that is designed for patients suffering from diabetes in China. Through a partnership collaboration with Covestro, QS Medical Technology produced high-quality needle-free injectors that offer more comfort and efficiency in the injection experience and help boost the compliance with medication.

READ
5 Healthcare Technologies Transforming Aging In Place

Similarly, a biotechnology company, GeoVax Labs, Inc. that develops human vaccines collaborated with PharmaJet to evaluate the company’s needle-free injection system against conventional needles and syringes for administering the Zika vaccine by GeoVax.

With burgeoning innovations and new product offerings in the needle-free injectors that boost the efficacy of drug delivery, needle-free injectors are here to stay.

Manufacturers Mulling over Increasing Commercialization of Needle-free Injectable Drug Delivery

Needle-free injectable drug delivery being the most prevailing product type, the manufacturers are focusing on grabbing profitable opportunities associated with the increasing preference given to this type. Commercialization and marketing of needle-free injectable drug delivery systems play a vital role in gaining profitability. On account of this, Namaste Technologies Inc. signed a definitive agreement with Inolife R&D Inc. With this agreement, Inolife R&D Inc. was granted exclusive rights to commercialize the innovative needle-free technology by Namaste Technologies Inc. In accordance with Health Canada, the needle-free technology would be used for the application of medical cannabis.

According to the company, the use of needle free injectors is an effective means of dosing through painless devices that also offer a rapid absorption rate. Such steps taken for the commercialization of injectable drug delivery are expected to contribute to the greater profits for manufacturers.

Final thoughts What Lies Ahead in the Injectable Drug Delivery Landscape?

According to a recent study presented by Future Market Insights, the injectable drug delivery market is expected to register peak growth with an increasing emphasis gained by point-of-care devices and the growing demand for pain free drug delivery. Furthermore, the prevalence of chronic diseases is creating greater demand for drugs, further driving the revenue of the injectable drug delivery market.